
Ninety percent of children and adults with acute lymphoblastic leukemia who had relapsed multiple times or failed to respond to standard therapies went into remission after receiving an investigational personalized cellular therapy, CTL019, researchers report.
http://feeds.sciencedaily.com/~r/sciencedaily/~3/pmAdsX8Kl8Q/141015190826.htm